Empery Asset Management Alleges Clinical Trial Misrepresentations By Seelos Therapeutics
Portfolio Pulse from Bill Haddad
Empery Asset Management has accused Seelos Therapeutics of misrepresenting clinical trial data. The asset management firm alleges that Seelos has been misleading investors about the progress and results of its clinical trials.
October 10, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Seelos Therapeutics has been accused by Empery Asset Management of misrepresenting clinical trial data. This could potentially impact investor trust and the company's stock price.
The allegations by Empery Asset Management could potentially harm investor trust in Seelos Therapeutics. If investors believe the allegations, they may sell their shares, leading to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100